AYTU BIOPHARMA, INC Selling, General and Administrative Expense
AYTU BIOPHARMA, INC (AYTU) reported Selling, General and Administrative Expense of $12.85 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2021-05-17
- AYTU BIOPHARMA, INC selling, general and administrative expense for the quarter ending 2021-03-31 was $12.85M, a 39.83% increase year-over-year.
- AYTU BIOPHARMA, INC selling, general and administrative expense for the quarter ending 2020-12-31 was $12.85M, a 97.24% increase year-over-year.
- AYTU BIOPHARMA, INC selling, general and administrative expense for the quarter ending 2020-09-30 was $11.49M, a 123.27% increase year-over-year.
- AYTU BIOPHARMA, INC selling, general and administrative expense for the quarter ending 2020-06-30 was $15.31M, a 212.65% increase year-over-year.
- AYTU BIOPHARMA, INC selling, general and administrative expense for fiscal 2020 was $34.80M, a 84.26% increase from fiscal 2019.
- AYTU BIOPHARMA, INC selling, general and administrative expense for fiscal 2019 was $18.89M, a 6.52% increase from fiscal 2018.
- AYTU BIOPHARMA, INC selling, general and administrative expense for fiscal 2018 was $17.73M, a 1.66% increase from fiscal 2017.
- AYTU BIOPHARMA, INC selling, general and administrative expense for fiscal 2017 was $17.44M, a 104.78% increase from fiscal 2016.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2021-03-31 | $12.85M 10-Q · filed 2021-05-17 | $25.70M derived: sum of 2 quarters · filed 2021-05-17 | $35.83M 10-Q · filed 2021-05-17 | $52.50M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2020-12-31 | $12.85M 10-Q · filed 2021-02-11 | $24.34M 10-Q · filed 2021-02-11 | $39.65M derived: sum of 3 quarters · filed 2021-02-11 | $48.84M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2020-09-30 | $11.49M 10-Q · filed 2020-11-12 | $26.80M derived: sum of 2 quarters · filed 2020-11-12 | $35.99M derived: sum of 3 quarters · filed 2021-05-17 | $42.50M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2020-06-30 | $15.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $24.50M derived: sum of 2 quarters · filed 2021-05-17 | $31.01M derived: sum of 3 quarters · filed 2021-05-17 | $34.80M 10-K · filed 2020-10-06 | |||
| 2020-03-31 | $9.19M 10-Q · filed 2021-05-17 | $9.50M 10-Q · filed 2020-05-15 | $15.71M derived: sum of 2 quarters · filed 2021-05-17 | $19.49M 10-Q · filed 2021-05-17 | $21.16M 10-Q · filed 2020-05-15 | $25.75M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $6.52M 10-Q · filed 2021-02-11 | $11.66M 10-Q · filed 2021-02-11 | $16.56M derived: sum of 3 quarters · filed 2021-02-11 | $21.93M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2019-09-30 | $5.15M 10-Q · filed 2020-11-12 | $10.04M derived: sum of 2 quarters · filed 2020-11-12 | $15.41M derived: sum of 3 quarters · filed 2020-11-12 | $20.46M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-06-30 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $10.27M derived: sum of 2 quarters · filed 2020-10-06 | $15.31M derived: sum of 3 quarters · filed 2020-10-06 | $18.89M 10-K · filed 2020-10-06 | |||
| 2019-03-31 | $5.37M 10-Q · filed 2020-05-15 | $10.41M derived: sum of 2 quarters · filed 2020-05-15 | $13.99M 10-Q · filed 2020-05-15 | $17.91M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $5.05M 10-Q · filed 2020-02-14 | $8.62M 10-Q · filed 2020-02-14 | $12.55M derived: sum of 3 quarters · filed 2020-02-14 | $17.18M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2018-09-30 | $3.58M 10-Q · filed 2019-11-14 | $7.50M derived: sum of 2 quarters · filed 2019-11-14 | $12.14M derived: sum of 3 quarters · filed 2019-11-14 | $16.69M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $8.56M derived: sum of 2 quarters · filed 2019-09-26 | $13.11M derived: sum of 3 quarters · filed 2019-09-26 | $17.73M 10-K · filed 2019-09-26 | |||
| 2018-03-31 | $4.64M 10-Q · filed 2019-05-14 | $9.19M derived: sum of 2 quarters · filed 2019-05-14 | $13.81M 10-Q · filed 2019-05-14 | $17.52M derived: sum of 4 quarters · filed 2019-05-14 | |||
| 2017-12-31 | $4.55M 10-Q · filed 2019-05-14 | $9.17M 10-Q · filed 2019-05-14 | $12.88M derived: sum of 3 quarters · filed 2019-05-14 | $17.27M derived: sum of 4 quarters · filed 2019-05-14 | |||
| 2017-09-30 | $4.62M 10-Q · filed 2018-11-07 | $8.33M derived: sum of 2 quarters · filed 2018-11-07 | $12.71M derived: sum of 3 quarters · filed 2018-11-07 | $16.36M derived: sum of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $8.10M derived: sum of 2 quarters · filed 2018-09-06 | $11.74M derived: sum of 3 quarters · filed 2018-09-06 | $17.44M 10-K · filed 2018-09-06 | |||
| 2017-03-31 | $4.39M 10-Q · filed 2018-05-14 | $8.03M derived: sum of 2 quarters · filed 2018-05-14 | $13.73M 10-Q · filed 2018-05-14 | $16.83M derived: sum of 4 quarters · filed 2018-05-14 | |||
| 2016-12-31 | $3.64M 10-Q · filed 2018-02-08 | $9.35M 10-Q · filed 2018-02-08 | $12.45M derived: sum of 3 quarters · filed 2018-02-08 | $14.61M derived: sum of 4 quarters · filed 2018-02-08 | |||
| 2016-09-30 | $5.70M 10-Q · filed 2017-11-09 | $8.81M derived: sum of 2 quarters · filed 2017-11-09 | $10.97M derived: sum of 3 quarters · filed 2017-11-09 | $12.66M derived: sum of 4 quarters · filed 2017-11-09 | |||
| 2016-06-30 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $5.27M derived: sum of 2 quarters · filed 2017-08-31 | $6.95M derived: sum of 3 quarters · filed 2017-08-31 | $8.52M 10-K · filed 2017-08-31 | |||
| 2016-03-31 | $2.17M 10-Q · filed 2017-05-11 | $2.24M 10-Q · filed 2016-05-11 | $3.85M derived: sum of 2 quarters · filed 2017-05-11 | $5.42M 10-Q · filed 2017-05-11 | $5.67M 10-Q · filed 2016-05-11 | $6.46M derived: sum of 4 quarters · filed 2017-05-11 | |
| 2015-12-31 | $1.69M 10-Q · filed 2017-02-09 | $1.77M 10-Q · filed 2016-02-11 | $3.25M 10-Q · filed 2017-02-09 | $3.43M 10-Q · filed 2016-02-11 | $4.30M derived: sum of 3 quarters · filed 2017-02-09 | $5.37M derived: sum of 4 quarters · filed 2017-02-09 | |
| 2015-09-30 | $1.56M 10-Q · filed 2016-11-07 | $1.71M 10-Q · filed 2015-11-06 | $2.61M derived: sum of 2 quarters · filed 2016-11-07 | $3.68M derived: sum of 3 quarters · filed 2016-11-07 | $4.43M derived: sum of 4 quarters · filed 2016-11-07 | ||
| 2015-06-30 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $2.12M derived: sum of 2 quarters · filed 2016-09-01 | $2.87M derived: sum of 3 quarters · filed 2016-09-01 | $3.98M 10-K · filed 2016-09-01 | |||
| 2015-03-31 | $1.07M 10-Q · filed 2016-05-11 | $1.82M derived: sum of 2 quarters · filed 2016-05-11 | $2.93M 10-Q · filed 2016-05-11 | ||||
| 2014-12-31 | $749.84K 10-Q · filed 2016-02-11 | $1.86M 10-Q · filed 2016-02-11 | |||||
| 2014-09-30 | $1.13M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |